contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


gubra-another-strong-quarter-in-cro-and-pipeline-update

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

CEO, Sweden

Claus Thestrup

Gubra er en medicinalvirksomhed. Virksomhedens aktiviteter er fokuseret på de tidlige stadier af lægemiddeludvikling. De udfører hovedsageligt forskning og udvikling inden for stofskifte- og fibrotiske sygdomme.Virksomhedens produktportefølje omfatter flere brands og lægemidler, og aktiviteterne foregår på globalt plan med den største tilstedeværelse i Nordamerika og Norden. Hovedkontoret ligger i Hørsholm, Danmark.

Gubra

Today, Gubra reported its Q3 2024 results. The company saw another strong quarter in the CRO business, driven by obesity service which is a major topic for the biotech and pharma industry.Read more here. 

The company saw another strong quarter in the CRO business, driven by obesity service which is a major topic for the biotech and pharma industry. However, they also experienced strong growth in the kidney service due to development of a large model catalogue over the last couple of years.
In the D&amp;P business advanced internal anti-obesity asset, Amylin GUBamy, continues according to plan. Gubra completed dosing of the key cohorts in June (cohorts 1-4)&#xa0;in the Phase 1 SAD-study. Based on a favourable safety profile, Gubra was able to dose the additional optional high-dose cohort five and six during the third quarter with customary follow-up visits completed at the beginning of October. The company expects to topline results of the study this month. In parallel, the company initiated the Multiple Ascending Dose study (MAD) in September.
Aside from Amylin, Gubra&apos;s urocortin-2 (UCN2) program for high quality weight loss is being prepared for further development. The compound holds great potential, pre-clinical co-administration studies showed that UCN2 completely prevents the lean mass loss observed in diet-induced obese rats treated with either GLP-1 or Amylin agonists while improving fat mass loss. The non-clinical toxicity program starts in the fourth quarter of 2024 and planning is ongoing for a clinical study potentially to be initiated in late 2025 or early 2026.
For partnered projects, Gubra, together with partner Boehringer Ingelheim (BI), in July announced the launch of a Phase 1 study of BI 3034701, a long-acting triple agonist peptide with a potential to become a next-generation and first-in-class obesity treatment. For another collaboration project with BI, NPY2R agonist, it was announced in October 2024 that BI will discontinue the development of this compound.
Guidance for 2024 upgraded:
Previous outlook 2024:
CRO segment:
Organic revenue growth 23-28%
Adjusted ebit-margin 29-32%
Updated outlook 2024:
CRO segment:
Organic revenue growth 26-28%
Adjusted ebit-margin 30-32%
In the D&amp;P segment they keep their previous guidance:
Number of partnerships per 1-2
Total costs (adjusted) DKK 160-170m
Total costs excl. Amylin asset (adjusted) DKK 115-125m
We host an event with Gubra later today &#x2013; sign up here: <a href="https://www.inderes.dk/videos/gubra-presentation-of-q3-2024" target="_blank" rel="noopener">Gubra event today</a>
Disclaimer:&#xa0;HC Andersen Capital receives payment from Gubra for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 9:00 (updated 09:15) 07.11-2024.

HC Andersen Capital

Gubra: Another strong quarter in CRO and pipeline update

Probabilities of success in drug development

Return on capital (ROE, ROI, ROIC, RONIC)

Helsinki Stock Exchange is cheap

Drug development investment: Value creation through M&As and licensing agreements

Valuation methods: Valuation multiples

Gubra

Tilmeld dig vores nyhedsbrev - ingen konto nødvendig!